HUAWEI continues to challenge the narrative surrounding its situation in international markets with the HUAWEI MatePad Pro 12.2 (2025), a premium tablet that excels in virtually every key area, except ...
The FDA has approved Astellas’s zolbetuximab (Vyloy) for HER2-negative, claudin-18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. It is the first CLDN18.2-targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results